Displaying 1 - 11 of 11
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024

View
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: A roadmap to functional cure (Complete Session) - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Displaying 1 - 11 of 11